l General Information |
Product Name | Dasatinib |
General description | Dasatinib is a pyrimidine and thiazole derived antineoplastic agent and protein kinase inhibitor of BCR-ABL kinase. |
Synonym | N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; Sprycel; BMS-354825; |
Purity | ≥99%(HPLC) | CAS Number | 302962-49-8 |
Formula | C22H26ClN7O2S | Molecular Weight | 488.007 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white to yellow powder |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Very slightly soluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Dasatinib Anhydrous is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or of the endogenous protein and by way of virally-encoded kinase genes. |
Application | 1. Protein Kinase Inhibitors 2. Antineoplastic Agents |
l Packaging & Storage |
Packaging | 250mg;1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
